Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.
Details
Download: 29296621_BIB_73E580433B39.pdf (202.20 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_73E580433B39
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.
Journal
Annals of clinical and translational neurology
ISSN
2328-9503 (Print)
ISSN-L
2328-9503
Publication state
Published
Issued date
12/2017
Peer-reviewed
Oui
Volume
4
Number
12
Pages
915-920
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.
Pubmed
Web of science
Open Access
Yes
Create date
15/01/2018 19:01
Last modification date
20/08/2019 15:31